Hiroaki Shirahase

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Kyoto Pharmaceutical Industries, Ltd., Sankyo Company, Limited. Active years: 1996-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroaki Shirahase. Retrieved from https://idiyas.com/inventor/hiroaki-shirahase

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 62.5

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 51(Granted Patents)

Location History:

Nagaokakyo, JP (1996 - 2009)
Kyoto, JP (2001 - 2021)

Company Filing History:

13 out of 26

Kyoto Pharmaceutical Industries, Ltd.

patents

3 out of 613

Sankyo Company, Limited

patents

Years Active: 1996-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11013728 - Cyclin-dependent kinase 8 and/or 19 inhibitor (2021-05-25),

2. 10059663 - Aromatic compound and use thereof (2018-08-28),

3. 7557123 - Heterocyclic compound and medicinal use thereof (2009-07-07),

4. 7429612 - Indoline compound and medicinal use thereof (2008-09-30),

5. RE38970 - Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors (2006-02-06),

6. 6872732 - Heterocyclic derivatives and medicinal use thereof (2005-03-29),

7. 6589963 - Heterocyclic compounds and salts thereof and medicinal use of the same (2003-07-08),

8. 6414012 - Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof (2002-07-02),

9. 6262108 - Medicinal use of cromoglycic acid compounds (2001-07-17),

10. 6201011 - Therapeutic agent for allergic dermatitis (2001-03-13),

11. 6200988 - Heterocyclic derivatives and pharmaceutical use thereof (2001-03-13),

12. 6149923 - Antirheumatic agent (2000-11-21),

13. 6127403 - Method for inhibiting acyl-CoA : cholesterol acyltransferase (2000-10-03),

14. 6063806 - Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or (2000-05-16),

15. 5990150 - Heterocyclic derivatives, method of production thereof and (1999-11-23),

Title: Hiroaki Shirahase: Innovator in Cancer and Bone Health

Introduction

Hiroaki Shirahase is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the fields of cancer treatment and bone health through his innovative research and development. With a total of 16 patents to his name, Shirahase has established himself as a key figure in pharmaceutical advancements.

Latest Patents

Among his latest patents, Shirahase has developed a cyclin-dependent kinase 8 and/or 19 inhibitor. This invention aims to provide a novel anti-cancer agent that can be used for preventing and treating cancer. The patent describes a compound represented by a specific formula, which includes pharmaceutically acceptable salts as active ingredients. Additionally, he has created an aromatic compound that promotes bone formation and suppresses bone resorption. This compound is designed to treat metabolic bone diseases such as osteoporosis and Paget's disease, showcasing low toxicity and good pharmacokinetics.

Career Highlights

Shirahase has worked with notable companies in the pharmaceutical industry, including Kyoto Pharmaceutical Industries, Ltd. and Sankyo Company, Limited. His work in these organizations has allowed him to focus on developing innovative solutions for pressing health issues.

Collaborations

Throughout his career, Shirahase has collaborated with esteemed colleagues such as Hiroshi Matsui and Shohei Nakamura. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Hiroaki Shirahase's contributions to cancer treatment and bone health through his patents highlight his innovative spirit and dedication to improving human health. His work continues to inspire advancements in the pharmaceutical field.

Profile summary based on public USPTO records.